Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
| 1.59 | |
| 1.52 | |
| - | |
| 1.63 | |
| 1.4 | |
| 1.05-3.77 | |
| 124 M | |
| 82 174 K | |
| 0 | |
| -0.35 | |
| 1.693 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
REDWOOD CITY, Calif. & BOSTON, January 25, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell thera...
REDWOOD CITY, Calif. & BOSTON, January 23, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. ("Adicet") (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
